1. Home
  2. BRCB vs IMMX Comparison

BRCB vs IMMX Comparison

Compare BRCB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRCB

Black Rock Coffee Bar Inc.

N/A

Current Price

$12.26

Market Cap

261.8M

Sector

N/A

ML Signal

N/A

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$8.58

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRCB
IMMX
Founded
2008
2014
Country
United States
United States
Employees
2800
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.8M
306.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BRCB
IMMX
Price
$12.26
$8.58
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$26.83
$19.00
AVG Volume (30 Days)
615.2K
725.5K
Earning Date
03-03-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.77
N/A
Revenue Next Year
$24.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.51
$1.34
52 Week High
$30.40
$11.61

Technical Indicators

Market Signals
Indicator
BRCB
IMMX
Relative Strength Index (RSI) 31.47 47.72
Support Level $11.51 $2.20
Resistance Level $17.60 $8.97
Average True Range (ATR) 1.10 0.95
MACD -0.39 -0.29
Stochastic Oscillator 5.46 14.68

Price Performance

Historical Comparison
BRCB
IMMX

About BRCB Black Rock Coffee Bar Inc.

Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: